Molecular Pharmacology Fast Forward. Published on June 27, 2007 as doi:10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

MOL #38158

Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein coupled receptor PAR1

Cecily E. Hamill[1,2], W. Michael Caudle[2,3], Jason R. Richardson[2,3], Hongjie Yuan[1], Kurt D. Pennell[2,4], James G. Greene[5], Gary W. Miller[2,3], and Stephen F. Traynelis[1]

1. Department of Pharmacology
Emory University School of Medicine
Atlanta, GA 30322 (CEH, HY, SFT)

2. Center for Neurodegenerative Disease
Emory University School of Medicine
Atlanta, GA 30322 (CEH, WMC, JRR, GWM)

3. Department of Environmental and Occupational Health
Emory University Rollins School of Public Health
Atlanta, GA 30322 (WMC, JRR, GWM)

4. Department of Civil and Environmental Engineering
Georgia Institute of Technology
Atlanta, GA, 30332 (KDP)

5. Department of Neurology
Emory University School of Medicine
Atlanta, GA 30322 (JGG)

Address correspondence to Stephen F. Traynelis strayne@emory.edu

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

MOL #38158

Running Title: **Increased damage in a model of Parkinson's disease by PAR1**

Cecily E. Hamill[1,2], W. Michael Caudle[2,3], Jason R. Richardson[2,3], Hongjie Yuan[1], Kurt D. Pennell[2,4], James G. Greene[5], Gary W. Miller[2,3], and Stephen F. Traynelis[1]

Number of pages: 37
Number of tables: 3
Number of figures: 6
Number of references: 102
Number of words in abstract: 170
Number of words in introduction: 652
Number of words in discussion: 1462

List of Non-standard abbreviations
PAR1—protease-activated receptor-1
MPTP—1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
DAT—dopamine transporter
TH—tyrosine hydroxylase
DA—dopamine
MMP1-matrix metalloprotease-1

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

Abstract

Protease-activated receptor 1 (PAR1) is a G-protein-coupled receptor activated by serine proteases and expressed in astrocytes, microglia, and specific neuronal populations. We examined the effects of genetic deletion and pharmacologic blockade of PAR1 in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease, a neurodegenerative disease characterized by nigrostriatal dopamine damage and gliosis. Following MPTP injection, PAR1-/- mice showed significantly higher residual levels of dopamine, dopamine transporter, tyrosine hydroxylase, and diminished microgliosis compared to wild-type mice. Comparable levels of dopaminergic neuroprotection from MPTP-induced toxicity were obtained by infusion of the PAR1 antagonist, BMS-200261 into the right lateral cerebral ventricle. MPTP administration caused changes in the brain protease system including increased levels of mRNA for two PAR1 activators, matrix metalloprotease-1 and Factor Xa, suggesting a mechanism by which MPTP administration could lead to overactivation of PAR1. We also report that PAR1 is expressed in human *substantia nigra pars compacta* glia as well as tyrosine hydroxylase-positive neurons. Together these data suggest that PAR1 might be a target for therapeutic intervention in Parkinson's disease.

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

Introduction

Parkinson's disease is a neurodegenerative disease characterized by bradykinesia, tremor, loss of dopaminergic neurons in the *substantia nigra pars compacta*, the appearance of Lewy bodies, and a reduction in dopaminergic projection terminals to the striatum (Olanow and Tatton, 1999). Although some Parkinson's cases have been linked to genetic mutations, the majority of cases are idiopathic (Olanow and Tatton, 1999). Whereas current therapy focuses on restoration of dopamine, no treatments exist that alter progression of the disease.

While the causes of Parkinson's disease are not understood, considerable evidence suggests a role for gliosis in the etiology and progression of the disease. Microglia, the major immune cell in the CNS, are found at highest density in the ventral midbrain (Lawson et al., 1990; Kim et al., 2000). Post-mortem brain tissue from Parkinson's disease patients show elevated levels of reactive microglia compared to age-matched controls (McGeer et al., 1988; Vila et al., 2001; Ouchi et al., 2005). Ouchi et al. (2005) demonstrated that increased microglia correlates with duration of disease, and occurs concurrently with decreased levels of the dopamine transporter in Parkinson's disease patients. Further, epidemiological studies indicate that events leading to compromise of the blood-brain barrier increase the risk of Parkinson's disease, whereas daily use of non-aspirin non-steroidal anti-inflammatory drugs lowers risk of development by 40% (Taylor et al., 1999; Chen et al., 2003; Mayeux, 2003). Human and non-human primates exposed to the dopaminergic neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) show damage to the nigrostriatal dopamine system and increased reactive microglia years after the exposure, indicating chronic inflammation (Langston et al., 1983; Langston et al., 1999; McGeer et al., 2003). Treatments that dampen inflammation are neuroprotective in the MPTP model of Parkinson's disease in mice (Rousselet et al., 2002; Wu et al., 2002; Sanchez-Pernaute et al., 2004), suggesting that dopaminergic projections to striatum may be uniquely vulnerable to inflammation.

Protease-activated receptor 1 (PAR1) is a G-protein coupled receptor that is expressed in the mammalian brain (Weinstein et al., 1995; Niclou et al., 1998; Junge et al., 2004), with particularly high levels in glia and dopaminergic neurons (Weinstein et al., 1995; Hamill et al., 2005). Serine proteases cleave

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

the extracellular N-terminus of PAR1 at Arg41 to reveal a new N-terminus that acts as a tethered ligand, initiating a complex signaling cascade (Macfarlane et al., 2001). PAR1 function has been reported in neurons, astrocytes and microglia (Suo et al., 2002; Wang et al., 2002a; Junge et al., 2004; Hamill et al., 2005). Moreover, PAR1 activation plays multifaceted roles in a number of neuropathological situations (Gingrich and Traynelis, 2000; Macfarlane et al., 2001; Ruf, 2003; Wang and Reiser, 2003; Suo et al., 2004), including stimulation of astrocytic and microglial proliferation (Suo et al., 2002; Sorensen et al., 2003; Wang and Reiser, 2003; Nicole et al., 2005). PAR1 is expressed throughout the basal ganglia, including the *substantia nigra pars compacta* and striatum (Weinstein et al., 1995; Ishida et al., 2006). Direct injection of serine proteases into the nigrostriatal pathway is selectively toxic to dopaminergic neurons (Carreno-Muller et al., 2003; Choi et al., 2003a), although some of the damage may reflect protease receptors other than PAR1 (Choi et al., 2003b). Thrombin also can induce delayed injury to cortico-striatal cultures, with striatal damage dependent on PAR1 activation (Fujimoto et al., 2006). There also appears to be an upregulation of PAR1 in postmortem samples from human patients diagnosed with Parkinson's disease (Ishida et al., 2006). Here we examine whether PAR1 activation plays a role in degeneration of dopaminergic terminal projections to striatum in the mouse MPTP model of parkinsonism. In this study we utilized a moderate MPTP dosing paradigm that leads to damage of dopaminergic terminals (Tillerson et al., 2002), in an effort to model early events in Parkinson's disease. Our data suggest that removal or blockade of PAR1 can blunt the neurotoxic effects of MPTP on dopaminergic nerve terminals, raising the idea that PAR1 may be a plausible therapeutic target for Parkinson's disease.

Materials and methods

MPTP model of Parkinson's disease

Male PAR1+/- mice (>95%C57Bl/6; provided by Dr. Shaun Coughlin, University of California, San Francisco, CA; Connolly et al., 1996) were bred with wild-type female C57Bl/6 wild-type mice (The Jackson Laboratory; Bar Harbor, ME). Heterozygous littermates were bred to generate homozygous null mutants that

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

were 97.5% C57BL/6. These mice were backcrossed again with wild-type C57 Bl/6 mice (Jackson lab), and the homozygous littermate wild-type or PAR1-/- used to establish the colony (>98.8% C57Bl/6). PAR1-/- mice used in this study have been backcrossed > 7 generations with C57/Bl6 mice. Animals used for these studies were within five generations of the initial homozygous breeding pairs. All mice were maintained on a standard 12:12 hr light/dark cycle and given ad libitum access to food and water. All procedures were approved by the Emory University Institutional Animal Care and Use Committee.

Mice (age 90-120 days) were injected subcutaneously twice with 10 mg/kg MPTP or saline between the shoulder blades (7:00 h, 19:00 h; Tillerson et al., 2002). This level of MPTP produces sustained damage of dopaminergic terminal projections in striatum without overt loss of dopaminergic cells, mimicking the early stages of parkinsonian degeneration. Mice were sacrificed by decapitation at 2 or 7 days, and a 1 mm section of the striatum (+1 mm to bregma) was dissected for both the left and right hemispheres. The left hemisphere was used in HPLC analysis, while the right hemisphere was used for immunoblot analysis. Alternatively, mice were overdosed on sodium pentobarbital, transcardially perfused with phosphate-buffered saline (PBS), and the brains drop fixed in 4% paraformaldehyde for one week, cyroprotected in 20% sucrose, and cut into 40 μM coronal sections. Each experiment group contained at least 3 mice.

PAR1 antagonist BMS-200261 treatment

For studies involving pharmacologic blockade of PAR1, 3 day/1 μl per hour Alzet® Minipumps were used for drug delivery. Empty pumps with flow moderators were weighed and then filled with 6 mM BMS-200261 (chemical formula: transcinnamoyl-p-fluoroPhe-p-guanidinoPhe-Leu-Arg-NH2) (Bernatowicz et al., 1996) or 10 mM HEPES-buffered saline and re-weighed. Flow moderators were connected to a catheter, which was connected to an infusion cannula. Pumps were stored overnight at 37ºC in sterile saline (0.9% NaCl) to prime drug release. The following day, 90-120 day old mice were anesthetized using 5% isoflurane, placed in a small animal stereotaxic apparatus (Kopf Instruments) and maintained with 2% isoflurane. The scalp was shaved, cleaned, and opened with a scalpel. Using hemostats, a subcutaneous pocket was created between the shoulder blades for the minipump. A small burr hole was drilled 1 mm

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

lateral, 0.2 mm caudal from bregma (Hof et al., 2000), the cannula was lowered into the right ventricle (depth 2.5 mm ventral), affixed with dental cement (Hof et al., 2000), and the opening sutured shut. Placement was verified in a subset of animals by injection of 0.5 µl of Evan's blue. Mice recovered for 12 hours before treatment with MPTP. Because the minipump was placed between the shoulder blades, MPTP could not be administered as previously, and was alternatively injected subcutaneously into the flank. The same dosing regimen (10 mg/kg x 2) was used for the minipump-implanted animals. Mice were sacrificed by decapitation after two days survival.

High performance liquid chromatography

HPLC was performed as previously described (Richardson and Miller, 2004). Briefly, left striata were sonicated in 0.1 M perchloric acid with 347 µM sodium bisulfite and 134 µM EDTA, and centrifuged at 16,000×g for 20 min (4 °C). The supernatant was removed, centrifuged at 16,000×g, and analyzed for levels of dopamine, 3,4-dihydroxyphenylacetic acid and homovanillic acid by HPLC (Column, MD 150, 3.2 mm×8 cm, 8-channel coulometric electrode array; Model 5600, ESA Inc., Chelmsford, MA; femptomole sensitivity). Quantification was made by reference to calibration curves. To measure conversion of MPTP to MPP+, animals were injected intraperitoneally with 20 mg/kg MPTP or PBS (Giovanni et al., 1991). Following 90-minute survival, mice were sacrificed by decapitation and both striata were isolated, weighed, rapidly frozen on dry ice, and maintained at -80 ºC until HPLC analysis.

Immunoblot analysis for markers of dopaminergic neurons and for gliosis

Samples were homogenized in 320 mM sucrose and 5 mM HEPES containing protease-inhibitor cocktail (1 µM aprotinin, 1 µM leupeptin, and 1 µM pepstatin A), and centrifuged at 2000×g for 5 min. The supernatant was removed and centrifuged at 30,000×g for 30 min. The pellets were resuspended in the homogenization buffer, protein concentrations were measured, and samples were subjected to polyacrylamide gel electrophoresis (10%). Samples were electrophoretically transferred to a polyvinylidene

difluoride membrane and blocked with 7.5% nonfat milk in Tris-buffered saline comprised of (in mM) 135 NaCl, 2.5 KCl, 50 Tris and 0.1% Tween-20 (pH 7.4). Membranes were incubated in a monoclonal antibody to the dopamine transporter (rat anti-DAT antibody; Chemicon, Temecula, CA) in Tris-buffered saline with 2% nonfat milk diluted 1:5000. Antibody binding was detected using a goat anti-rat horseradish peroxidase secondary antibody (ICN, Costa Mesa, CA) and enhanced chemiluminescence (Pierce, Rockford, IL). The chemiluminescent signal was captured with an Alpha Innotech FluoroImager (Innotech, San Leandro, CA), stored as a digital image and analyzed. Membranes were then stripped for 15 min at 25°C (Pierce stripping buffer) and re-probed consecutively with a polyclonal rabbit tyrosine hydroxylase antibody (Chemicon; 1:375), a polyclonal rabbit GFAP antibody (Sigma, St. Louis, MO; 1:5000), a polyclonal rabbit GLUT5 antibody (Chemicon, 1:5000), and monoclonal mouse alpha-tubulin antibody (Sigma 1:5000). Rabbit primary antibodies were visualized with goat anti-rabbit secondary diluted 1:5000 (Bio-Rad, Hercules, CA). Mouse primary antibody was visualized with goat anti-mouse secondary diluted 1:10,000 (Bio-Rad). For all, membranes were incubated in primary antibody for 8-12 hours at 4ºC and in secondary antibody for 1 hour at 25ºC. All samples were controlled for protein loading through normalization to the signal for tubulin.

Immunohistochemistry

Human tissue was obtained by Emory University Hospital Autopsy Service from patients who died from non-neurologic causes and whose brains were free of evidence of neurodegenerative disease. Tissue was obtained from four patients: two males (age 70 and 40) and two females (age 74 and 57). Tissue was fixed in 4% paraformaldehyde, paraffin embedded and cut into 8 μm sections. Paraffin was removed and sections were rinsed/incubated in 3% hydrogen peroxide to quench endogenous peroxidases. To remove neuromelanin, sections were incubated in 2.5% potassium permanganate (30 minutes) and 5% oxalate solution (5 minutes). Sections were rinsed and microwaved in citrate buffer (10 mM citrate monohydrate; 10 minutes). After cooling, sections were blocked in normal goat serum and incubated in the monoclonal PAR1 antibody (WEDE15; 1:200) and/or polyclonal rabbit tyrosine hydroxylase antibody (Chemicon; 1:1000) for 48 hours at 4ºC. PAR1 signal was visualized with tyramide-signal amplification with Alexa fluor 546-

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

conjugated tryamide (Molecular Probes, Eugene, OR). Tyrosine-hydroxylase signal was visualized with Alexa fluor 488-conjugated secondary antibody. Primary antibody was excluded for negative controls.

Mouse brain sections were incubated in 3% hydrogen peroxide (10 minutes) and blocked in 10% NGS, and incubated overnight at 4ºC in antibody against tyrosine hydroxylase (Chemicon 1:1000), dopamine transporter (Chemicon, 1:1000), or anti-GFAP (Sigma, 1:5000). Sections were then incubated in biotin-conjugated goat anti-mouse antibody (Jackson ImmunoResearch; 1:200) and signal detected using the avidin-biotin complex method of staining (which contains avidin complexed to peroxidase, Vector Labs, Burlingame, CA) and visualized with 3,3-diaminobenzidine tetrachloride (Sigma). For GFAP, staining was visualized using a Cy3-conjugated secondary antibody (goat-anti rabbit, Jackson ImmunoResearch, West Grove, PA, 1:200). Staining for MAC-1 was similar except that slices were incubated in primary antibody (Serotec; Raleigh, NC; 1:500) for 48 hours at 4ºC before secondary incubation (biotin-conjugated goat anti-rat; Jackson ImmunoResearch). For IB4 microglia staining, slices were incubated for 2 hours with Cy3-conjugated IB4-lectin in a solution comprised of (in mM) 22 sucrose, 10 glucose, 150 NaCl, 10 HEPES, 3 KCl, 2 $CaCl_2$., 1 Mg`Cl_2. Blood-brain-barrier permeability staining was performed as previously described (Schmidt-Kastner et al., 1993). Sections were then incubated in biotin-conjugated goat secondary antibody (Jackson ImmunoResearch; 1:200) and signal detected using the avidin-biotin complex method (Vector Labs), and visualized with 3,3-diaminobenzidine tetrachloride (Sigma). Median eminence was examined as a positive control as this region normally has no blood-brain barrier.

Synaptosomal Dopamine and MPP+ Uptake, and ^{3}H-WIN 35,428 Binding

Dopamine uptake studies were performed as described previously (Elwan et al., 2006). Briefly, crude synaptosomes were prepared from striatal tissue and incubated in assay buffer comprised of (in mM) 4 Tris, 6.25 HEPES, 120 NaCl, 5 KCl, 1.2 $CaCl_2$, 1.2 $MgSO_4$, 0.6 ascorbate, 5.5 glucose, and 0.01 pargyline; pH 7.4 containing a saturating concentration of dopamine (1 µM) and trace amount of ^{3}H-dopamine (20 nM). Similarly, MPP+ uptake was performed with a single concentration of MPP+ (1 µM) and trace amount of ^{3}H-MPP+ (20 nM). Uptake proceeded for 3 min at 37ºC and was terminated by adding ice-cold buffer, followed

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

by vacuum filtration over GF/B filter paper. Filters were washed twice, air-dried, and placed in scintillation vials containing 8 ml of Econoscint (Fisher Scientific, Pittsburgh, PA) for scintillation counting. Uptake rates were calculated from total uptake minus non-specific uptake, with non-specific uptake defined by the inclusion of 10 µM nomifensine for both dopamine and MPP+ studies. Following determination of synaptosomal protein concentration (Bradford, 1976), uptake rates were calculated and expressed as pmol/(min mg protein).

Determination of ^{3}H-WIN 35,428 binding to the dopamine transporter was performed as previously described (Coffey and Reith, 1994) with modifications to reduce the total volume to 200 µl in 96-well microtiter plates (Elwan et al., 2006). Briefly, binding studies with crude synaptosomes were conducted with a single concentration (10 nM) of ^{3}H-WIN 35,428 in 25 mM sodium phosphate buffer for one hour at 4ºC. Incubations were terminated by vacuum filtration onto GF/B filter plates; radioactivity was determined by liquid scintillation counting. Non-specific binding was determined by the inclusion of 10 µM nomifensine and specific binding was calculated as the total binding minus non-specific binding. All experiments were performed at room temperature (23ºC).

Extraction of mRNA and quantitative reverse transcriptase PCR

Extraction of mRNA was performed as described by the manufacturer (Qiagen, Valencia, CA). RNA was eluted into 50 µl of RNAse-free water, and concentrations measured using a spectrophotometer (Eppendorf ® Biophotometer, wavelength 260/280 nm). cDNA was generated using 1 µg of RNA, 10 µl of 10X random primers, and MultiScribe™ Reverse Transcriptase (Applied Biosystems, Foster City, CA). The solutions were brought to 50 µl with RNAse-free water, and incubated at 25ºC (10 min) and at 37ºC (2 hours). Samples were stored at -20ºC.

Real-time PCR was performed using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Bedford, MA). Reactions were performed in a total volume of 25 µl using SyBr Green Master Mix (Applied Biosystems); 2 µl of cDNA template synthesized as described above per sample was used, with 10 µM of forward and reverse primers; the final concentration of template was 40 ng/reaction. Both the

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

target and 18S amplifications were performed in duplicate. Thermal cycling conditions included 2 min at 50°C, 10 min at 95°C, followed by 40 cycles at 95°C for 15 s and 1 min at the annealing temperature. Primers for MAC-1(CD11b) were as follows: forward primer 5'-tgtgccgagtcgctgaagtttgat-3', reverse primer 5'-ctaccacggtgccccctacgat-3'. Primers for protease, protease inhibitors, and protease-activated receptors were obtained from SuperArray Bioscience and used as specified (Frederick, MD). To normalize the amount of total mRNA present in each reaction, levels of the 18S ribosomal subunit were monitored in parallel samples. Results were expressed as relative levels of mRNA, referred to as control samples chosen to represent 1x gene expression. The amount in the treated sample, normalized to reference (18S) and relative to the control sample, was defined by the Ct method (Livak and Schmittgen, 2001). Primer sets yielded a single PCR product as monitored using melting curves in each reaction well.

Ventral midbrain cultures and treatment

Ventral midbrain was dissected from embryonic (E14.5) C57Bl/6 mice and pooled in Dulbecco's phosphate-buffered saline without calcium or magnesium. Tissue was washed twice and dissociated using the Papain Dissociation System from Worthington Biochemicals. Briefly, tissue was incubated for 1 hour at 37 ºC in Earle's balanced salt solution (EBSS) containing 20 U/ml papain, 1 mM L-cysteine, 0.5 mM EDTA, and 100 U/ml DNase, and then triturated through a fire-polished pasteur pipette followed by a 1.5 inch 22G needle. The tissue suspension was centrifuged at 300xg for 5 min, cells were taken up in 2 ml of protease inactivating solution (EBSS containing 10% ovomucoid protease inhibitor and 100 U/ml DNase), layered onto 4 ml of ovomucoid protease inhibitor, and centrifuged at 70G for 7 min. Cells were taken up in 2 ml of plating medium (Gibco Neurobasal supplemented with B27 supplement, 2% FBS, 30 mM glucose, 0.5 mM glutamine, and 25 µg/ml gentamicin), counted using a hemacytometer, diluted to 600,000 cells/ml, plated in a 50 µl drop onto the center of a 12 mm coverslip coated with poly-D-lysine (10 µg/ml) and laminin (10 µg/ml), and placed in a 37 ºC incubator (5% CO_2; 100% relative humidity). Four hours later, wells (24-well plates) were topped up to 1 ml final volume using plating medium. After 24 hours in culture, plating medium was replaced with Neurobasal supplemented with B27 supplement, 30 mM glucose, 0.5 mM glutamine, 25

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

μg/ml gentamicin, and 5 ng/ml GDNF. Cells were used after 8-12 days in culture. Under these conditions, neurons (approximately 7% of which are tyrosine hydroxylase-positive) are the predominant cell type on top of a monolayer of astrocytes. Cultured mouse neurons were treated for 15 minutes at 37°C with vehicle or a maximally effective concentration (30 μM) of the PAR1-selective modified peptide agonist TFLLR-NH_2 (TFLLR; chemical structure: Thr-Phe-Leu-Leu-Arg-NH2, Hollenberg et al., 1997; Nicole et al., 2005). Neurons were then fixed in 4% paraformaldehyde at room temperature for 10 min and washed in phosphate-buffered saline three times, 0.1% Triton-X and blocked with 3% bovine serum albumin in Tris-buffered saline (TBS) for 20 min. Neurons were incubated overnight at 4°C in monoclonal mouse anti-tyrosine hydroxylase (1:1000; Chemicon, MA) and monoclonal rabbit antibody recognizing extracellular signal-regulated kinase that was phosphorylated at both threonine-202 and tyrosine-204 (phospho-ERK, 1:250, Cell Signaling, MA). After washing in TBS, neurons were incubated at room temperature in goat anti-mouse Alexa Fluor 488 (1:500; Invitrogen, CA) and goat anti-rabbit antibody conjugated to Texas red (1:200, 4 hours, Invitrogen, CA) for two hours. After rinsing three times with TBS, neurons were mounted with Vectashield medium (Vector Laboratories, CA) and viewed with Olympus IX71 microscope.

Statistics

Statistical evaluation was performed using unpaired t-test, 1-factor ANOVA with Newman-Keuls post-hoc test, or 2-factor ANOVA with Bonferroni post hoc test where appropriate. The number of observations are given in the figure legends or text; all F values and degrees of freedom for 2-factor ANOVAs are provided in Supplementary Table 1. $p<0.05$ was considered to be significant. Data are given as mean±SEM

Results

PAR1-/- mice show reduced MPTP-induced damage of nigrostriatal dopamine pathway

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

We used the mouse MPTP model of Parkinson's disease to determine whether PAR1 activation contributes to damage of the dopaminergic system. Reasoning that findings obtained using a model of early disease might identify clinically useful intervention strategies, we chose an MPTP dosing regimen that causes significant dopaminergic terminal destruction with little cell loss, thus mimicking the dying-back phenomena thought to occur in early PD (Aubin et al., 1998; Saporito et al., 1999; Schmidt and Ferger, 2001; Tillerson et al., 2002; Rommelfanger et al., 2004). For all parameters, MPTP induced a significant change compared to saline injected controls (Supplementary Table 1).

PAR1-/- mice showed considerably less striatal damage compared to age-matched wild-type controls 2 days following MPTP injection, as determined by immunohistochemistry (Fig. 1a) and protein levels of dopamine transporter and tyrosine hydroxylase (Fig. 1b), key markers of striatal integrity. Wild-type mice treated with MPTP lost 56$\pm$4% of the dopamine transporter and 42$\pm$4% of tyrosine hydroxylase compared to vehicle-treated controls. By contrast, the PAR1-/- mice treated with MPTP lost only 22$\pm$8% (Fig. 1b; $p<0.01$; 2-factor ANOVA) of the dopamine transporter and 8$\pm$6% (Fig. 1b; $p<0.01$; 2-factor ANOVA) of the tyrosine hydroxylase compared to vehicle-treated controls. These immunoblot results were supported by immunohistochemical analysis within the mouse striatum. Wild-type mice treated with MPTP showed a large reduction in dopamine transporter and tyrosine hydroxylase, as indicated by noticeably lighter staining in MPTP-treated wild-type mice compared to PAR1-/- mice (Fig. 1a). MPTP caused uniform decreases in dopamine transporter and tyrosine hydroxylase protein expression across wild-type striatum whereas PAR1-/- mice showed staining evenly throughout the striatum that was similar to saline-injected control mice.

To confirm that the reduction in damage to dopaminergic markers did not reflect simply a delay in damage in PAR1-/- mice, we analyzed mice one week and one month after MPTP treatment. As shown in Figure 1c, PAR1-/- mice showed significantly higher levels of dopamine transporter and tyrosine hydroxylase than vehicle-treated controls 7 days after MPTP treatment ($p<0.01$ for both; 2-factor ANOVA). This result was supported by immunohistochemistry, which revealed attenuated loss of dopamine transporter and tyrosine hydroxylase throughout the striatum in PAR1-/- mice following MPTP treatment (data not

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

shown; n=3). Similarly, we found that after 30 days, the PAR1-/- mice still maintained higher levels of striatal DAT and TH than their wild-type counterparts, documenting the persistence of the terminal damage and suggesting that long-term protective effects accompany the removal of PAR1 (Fig 1d; $p<0.1$ for both; 2-factor ANOVA).

PAR1-/- mice show reduced MPTP-induced dopamine loss

To evaluate the functional consequence of reduced expression of dopamine transporter and enzymes for dopamine synthesis, we measured striatal dopamine levels as well as the levels of metabolites 3,4-dihydroxy-phenylacetic acid and homovanillic acid. Again, the PAR1-/- mice had significantly higher residual levels of dopamine than their wild-type counterparts following MPTP exposure. Following two days, wild-type mice lost 54$\pm$5% of striatal dopamine whereas PAR1-/- mice lost 35$\pm$4% (Fig. 2a; $p<0.01$; 2-factor ANOVA). Similar results were seen for the dopamine metabolites (data not shown). The higher levels of dopamine indicate that not only are the dopaminergic terminals more structurally intact (as indicated by immunoblot data), but that the neurons also maintain metabolic activity close to normal levels. Dopamine from wild-type and PAR1-/- mice was also measured following a one week survival. PAR1-/- mice continued to show higher levels of dopamine than the wild-type mice. Following MPTP treatment, wild-type mice lost 66$\pm$2% of their dopamine; PAR1-/- mice lost 47$\pm$4% (Fig. 2b; $p<0.001$; 2-factor ANOVA). The protective effect observed in the PAR1-/- mice continues through 30 days survival. At this time point, PAR1-/- mice showed a decrease of 31$\pm$2% of their striatal dopamine whereas wild-type mice has a decrease 55$\pm$2% (Fig. 2c; $p<0.001$; 2-factor ANOVA).

PAR1 antagonist reduces MPTP-induced damage of nigrostriatal dopamine pathway

To ensure that the protection seen in PAR1-/- mice was specific to PAR1 and not due to epigenetic or compensatory changes in the knockout animal, we examined the role of PAR1 activation in MPTP-induced damage in wild-type mice by pharmacologically blocking the receptor with the selective PAR1 antagonist BMS-200261 (Bernatowicz et al., 1996, Kawabata et al., 1999). BMS-200261 potently

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

binds to PAR1 (K_D 20 nM) preventing cleavage at Arg41 from activating the receptor (Bernatowicz et al., 1996); 1 μM BMS-200261 is sufficient to fully block PAR1-induced Ca^{2+} signaling in atrocytes (Nicole et al., 2005). Antagonist was administered intracerebroventricularly via a brain cannula connected to an osmotic minipump. Mice received 1 μl/hour of 6 mM PAR1 antagonist or vehicle throughout the MPTP treatment and survival periods (approximately 6.2 mg/kg over 24 hours). If we assume a mouse brain volume of ~1 ml with 20% extracellular volume, this would provide a maximum concentration of 30 μM; assuming peptide degradation and removal reduce the concentration 10-fold, there should still be sufficient antagonist (3 μM) to block PAR1. Five sets of mice were treated to evaluate the effect of antagonist on the response to MPTP. We treated one set of mice with vehicle-loaded minipumps and saline injection and a second set of mice with antagonist-loaded minipumps and saline injection. These data sets showed no difference in dopamine transporter and tyrosine hydroxylase protein levels and therefore were combined. A third set of mice was treated with vehicle-loaded minipumps and MPTP injection while a fourth set of mice received no minipump and was injected subcutaneously with MPTP. The third and fourth sets of mice showed similar loss of biochemical markers and as such were combined. The fifth set of mice received antagonist-loaded minipump and subcutaneous MPTP injection. The results of this experiment showed that the mice treated with antagonist had significantly less damage following MPTP treatment than those that were not treated with antagonist. Mice that did not receive antagonist lost 40±6% of dopamine transporter and 37±7% of tyrosine hydroxylase, compared to antagonist-treated mice, which lost 2±5% of dopamine transporter and 19±5% of tyrosine hydroxylase (Fig. 3a; $p<0.01$ and $p<0.05$ respectively; 1-factor ANOVA).

Pharmacologic blockade of the PAR1 receptor with BMS-200261 also inhibited MPTP-induced dopamine loss. Mice that received saline infusion over 3 days lost 46±3% of their striatal dopamine, which was similar to wild-type mice that did not receive minipump implantation (54±5%). In contrast, mice that were treated with PAR1 antagonist lost only 25±3% of their dopamine, which was significantly different from vehicle-treated controls (Fig. 3b; $p<0.01$; 1-factor ANOVA). Together these data support our interpretation that the effects of PAR1 activation exacerbate MPTP-induced terminal damage.

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

PAR1-/- mice showed attenuated microglial responses following MPTP treatment

Microgliosis and astrogliosis have been shown to play a role in the damage seen in the MPTP model of Parkinson's disease (O'Callaghan et al., 1990; Kurkowska-Jastrzebska et al., 1999; McGeer et al., 2003). We measured several markers of gliosis in wild-type and PAR1-/- mice to determine whether PAR1 expression altered glial response to MPTP treatment. MPTP treatment increased the extent of microglial activation in striatum of wild-type mice (Fig. 4a), with cells assuming an activated phenotype with hypertrophic cell bodies and shorter processes (Fig. 4a, arrows; Kurkowska-Jastrzebska et al., 1999). By contrast, the microglial response was close to baseline in the PAR1-/- mice after MPTP injection (Fig. 4a). In PAR1-/- mice, most of the microglia retained small cell bodies and ramified processes (Fig. 4a). In order to determine effects of MPTP on microglia, we used RT-PCR to quantify in each treatment group the level of MAC-1(CD11b) mRNA, a microglial marker. Saline-treated wild-type and PAR1-/- mice had similar levels indicating no baseline genotypic differences (100$\pm$23% in wild-type mice versus 116$\pm$23% in PAR1-/- mice). Wild-type mice showed an increase of MAC-1(CD11b) mRNA following MPTP injection (343$\pm$77%). MPTP had no significant effect on MAC-1(CD11b) mRNA in PAR1-/- mice compared to wild-type mice (120$\pm$15%; $p<0.05$; 2-factor ANOVA). To quantify this microglial response on the protein level, we used immunoblot analysis of glucose transporter-5, another marker for microglia (Payne et al., 1997). We found no significant difference in glucose transporter-5 levels between the saline-treated wild-type and PAR1-/- animals (Fig. 4b). However, wild-type mice treated with MPTP showed 162$\pm$21% of glucose transporter-5 whereas PAR1-/- mice showed no significant increase following MPTP (Fig. 4b; $p<0.01$; 2-factor ANOVA). To test whether the effect of PAR1 on microglial activation was persistent, we repeated these studies following one week survival. Similar to that observed in mice by other studies (Francis et al., 1995; Czlonkowska et al., 1996; Kohutnicka et al., 1998; Liberatore et al., 1999), the microglial response had abated in wild-type mice by seven days post-injection, with sporadic phenotypically-activated microglia visible. However, no activated microglia were observed in any of the slices examined from PAR1-/- mice

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

(data not shown). These data indicate that the reduced presence of activated microglia at two days does not reflect a delay in microglial activation.

We studied the response of astrocytes to MPTP treatment by evaluating the astrocyte marker GFAP 2 or 7 days after MPTP injections. Although there was an upregulation of GFAP in both wild-type and PAR1-/- mice following MPTP, we found no difference between wild-type and PAR1-/- mice at 2 days or 7 days post injection by either immunoblot or immunohistochemistry (Fig. 4cd; 2 days; wild-type mice 151$\pm$18%, PAR1-/- mice 143$\pm$14%; $p>0.05$; 7 days; wild-type 212$\pm$29%, PAR1-/- 191$\pm$15%; $p>0.05$; 2-factor ANOVA).

As a control, we examined levels of activated and non-activated astrocytes and microglia before MPTP injection to determine whether PAR1-/- animals showed altered glial cell expression. PAR1-/- animals showed no difference of the astrocyte marker GFAP compared to wild-type controls (Fig. 4cd). Similarly, we found no difference in IB4 staining, a marker for both activated and non-activated microglia, between wild-type and PAR1-/- mice before MPTP injection (Fig. 5a). These data suggest that the attenuated microglial response in PAR1-/- mice reflected reduced activation by MPTP-dependent processes.

MPTP increases two known activators of PAR1

To evaluate the effects of MPTP on upstream factors controlling PAR1 activation, we measured the effects of MPTP on the mRNA levels of several central nervous system proteases. Some of these proteases directly activate PAR1 while others indirectly lead to PAR1 activation through activation of zymogen precursors of PAR1 activators (Liu et al., 1991; Vu et al., 1991; Blackhart et al., 1994; Kuliopulos et al., 1999; Altrogge and Monard, 2000; Blanc-Brude et al., 2001; Macfarlane et al., 2001; Jiang et al., 2004; Shi et al., 2004; Boire et al., 2005). MPTP caused no significant changes in mRNA levels determined by real time PCR for plasminogen or its activator, tissue plasminogen activator. Likewise, we found no difference in prothrombin factor VII, neurotrypsin, or protein C mRNA levels (Table 1). However, we did find that MPTP administration significantly increased MMP1 in both wild-type and PAR1-/- mice (Table 1; treatment $p<0.01$; 2-factor ANOVA). Likewise, MPTP induced an increase in Factor X mRNA in both genotypes

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

(Table 1; treatment $p<0.05$; 2-factor ANOVA). Thus, MPTP may stimulate PAR1 activation through increased production of direct and indirect activating proteases. We also evaluated whether MPTP might cause changes in PAR1 signaling by increasing receptor expression. However, we did not find an MPTP-induced change in mRNA for PAR1 or any of the other protease-activated receptors (Table 1; $p>0.05$; 2-factor ANOVA). Increased PAR1 signaling could also be mediated by a decrease in the expression of the protease inhibitors, which may act to dampen tonic PAR signaling through inhibition of serine protease activators. We found no significant changes in the mRNA levels for protease-nexin 1, neuroserpin, or tissue inhibitor of matrix metalloprotease-1 (Table 1; $p>0.05$; 2-factor ANOVA). However, there was a significant decrease in the expression of plasminogen-activator inhibitor-1 in both genotypes (Table 1; $p<0.05$; 2-factor ANOVA). This decrease indicates that there may be enhanced PAR1 signaling via the tPA-plasmin pathway. Plasminogen is present in CNS tissue and when converted to plasmin, is capable of activating PAR1 (Junge et al., 2003). These data suggest MPTP favors PAR1 activation through both increased transcription of a subset of PAR1 activators and decreased transcription of PAR1 inhibitors. This data also indicates that the mechanism of the protection observed in PAR1-/- mice is not due to altered response to MPTP in regard to these changes in gene expression as there was no significant effect of genotype (Table 1; $p>0.05$; 2-factor ANOVA).

Deletion of PAR1 does not alter dopamine transport, MPP+ levels, or blood-brain-barrier breakdown

Four control studies were performed to test whether the protection of nigrostriatal system observed in PAR1-/- mice reflects developmental differences that modified the response to MPTP. First, we found no significant difference in the expression of dopamine transporter in wild-type mice *vs* PAR1-/- mice, as measured using the radiolabeled ligand [^{3}H]WIN 35,428 (Table 2; wild-type 984$\pm$39 fmol/mg protein; PAR1-/- 1014$\pm$36 fmol/mg protein; $p>0.05$; t-test; Coffey and Reith, 1994; Elwan et al., 2006). Second, we tested whether the ability of the dopamine transporter to move dopamine or MPP+ into cells was different between wild-type and PAR1-/- animals. Dopamine uptake in pmol/(min mg protein) was 309$\pm$9 for wild-type mice and 306$\pm$17 for PAR1-/- mice (Table 2; n=3-4; $p>0.05$; t-test). Similarly, uptake of MPP+ was

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

indistinguishable between wild-type versus PAR1-/- mice (Table 2; 198±13 *vs* 195±18 pmol/(min mg protein), respectively; p>0.05; n=3-4; t-test). Third, we measured the ability of wild-type and PAR1-/- mice to convert MPTP to the active toxin MPP+. We found no difference in the level of the active neurotoxin MPP+, indicating that the protection in PAR1-/- mice was not due to decreased toxin exposure. Levels of MPP+ were 3.5±0.3 ng/mg tissue for wild-type and 3.2±0.2 ng/mg for PAR1-/- mice (Table 2; n=3-4; p>0.05; t-test). Fourth, we examined whether PAR1-/- mice had abnormalities in the permeability of their blood-brain-barrier following MPTP injection, since PAR1 is expressed in endothelial cells and may influence maintenance of the blood-brain-barrier (Riewald et al., 2002). We stained for the presence of serum-borne IgG (MW~150kD) into the brain parenchyma following MPTP injection and two-day survival, which would indicate compromised barrier function at this time point. Consistent with many other studies showing that MPTP does not alter blood-brain-barrier breakdown (Adams et al., 1989; O'Callaghan et al., 1990; Kurkowska-Jastrzebska et al., 1999), we were unable to detect IgG in the striata of either wild-type or PAR1-/- mice following MPTP injection, suggesting that the protection observed in PAR1-/- mice is not due to differences in blood-brain-barrier permeability (Fig. 5b). Together these data suggest that the protection seen in PAR1-/- mice did not reflect production or uptake of neurotoxic MPTP metabolites or altered permeability of the blood-brain barrier in PAR1-/- animals.

Expression of PAR1 in human and mouse dopaminergic neurons

Previous work has shown that PAR1 mRNA expression is highest in rat dopaminergic neurons (Weinstein et al., 1995; Ishida et al., 2006). Additional studies have co-localized PAR1 protein with astrocytic markers in the CNS of rats as well as humans (Weinstein et al., 1995; Niclou et al., 1998; Junge et al., 2004; Hamill et al., 2005; Ishida et al., 2006). We have used antibodies against PAR1 and tyrosine hydroxylase, a reliable marker of dopaminergic neurons, to examine whether PAR1 protein is present in the dopaminergic neurons of normal human substantia nigra pars compacta. Previous studies have found PAR1 protein expression in substantia nigra pars compacta astrocytes but not neurons (Ishida et al., 2006). Immunohistochemical analysis of four cases from normal patients all showed clear colocalization of

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

immunoreactivity for tyrosine hydroxylase and PAR1 in a subset of substantia nigra pars compacta cells; other tyrosine hydroxylase-positive cells lacked PAR1 immunoreactivity, suggesting PAR1 expression varies among dopaminergic neurons (Fig. 6a). On average about 71% of tyrosine hydroxylase-positive neurons also express PAR1. A subset of small cells expressed PAR1 but lacked tyrosine hydroxylase, which were likely to be glial cells (Junge et al., 2003; Hamill et al., 2005). These data provide evidence that PAR1 is expressed not only in astrocytes but in dopaminergic neurons of the substantia nigra.

We also tested for functional expression of PAR1 on mouse dopaminergic neurons. Ventral midbrain cultures were prepared from transgenic mice in which the GFP gene was controlled by the tyrosine hydroxylase promoter. This allowed us to identify dopaminergic neurons in culture. It has been previously shown that activation of PAR1 causes signaling via the MAP kinase pathway and phosphorylation of ERK (Macfarlane et al., 2001; Hollenberg, 2002; Wang et al., 2002b; Sorensen et al., 2003; Nicole et al., 2005). Following a 15 minute exposure to either vehicle or 30 μM TFLLR, coverslips containing neuronal cultures were fixed and stained for phospho-ERK and tyrosine hydroxylase (Nicole et al., 2005). The peptide agonist, TFLLR is known to be specific for PAR1 over other protease-activated receptors and was administered at a high dose (Hollenberg et al., 1997). Throughout the mixed culture of both dopaminergic and GABAergic neurons, astrocytes, and microglia, we saw a strong increase in phospho-ERK expression (Fig. 6b). In particular, we observed a clear co-localization of phospho-ERK and tyrosine hydroxylase in cultures treated with PAR1 activators, suggesting that there is functional expression of PAR1 in mouse dopaminergic neurons. Out of 24 tyrosine-hydroxylase positive neurons observed on three coverslips, 22 showed increased phospho-ERK staining.

Discussion

In this study we show that MPTP causes an upregulation of PAR1 activators and that genetic deletion or pharmacologic blockade of PAR1 protects mice from MPTP-induced damage as well as MPTP-triggered microglia activation. These data demonstrate that PAR1 activation can contribute to dopaminergic terminal damage in this model of early Parkinson's disease. Furthermore, we show that PAR1

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

is expressed in the dopaminergic neurons of human and mouse, suggesting that the results obtained in this animal model could have relevance for humans. Because protease-activated receptors such as PAR1 and PAR4 are known to influence microglial activation, (Suo et al., 2002; Nicole et al., 2005), these findings raise the idea that PAR1 activation may be an important molecular link between inflammation and damage to dopaminergic neurons in Parkinson's disease.

Activation of PAR1 and Parkinson's disease

The results of this study suggest that the proteases that activate PAR1 may influence the pathophysiology of Parkinson's disease, and focus attention on how potential activators or inhibitors of PAR1 might impact the disease progression. Previous studies that have examined PAR1 activation in the context of stroke and ischemia have provided a great deal of information about PAR1 signaling and neuroprotection as well as neuronal death. One view emerging is that PAR1 activation can have both harmful and helpful effects in ischemia that involve different pathways and different levels of PAR1 activation (Wang & Reiser, 2003). Ishida et al. (2006) suggest a similar paradigm may occur in models of Parkinson's disease, with the neurotoxicity of thrombin being mitigated by PAR1-activation of astrocytes. Cannon et al. (2005,2006) have presented evidence that thrombin preconditioning can reduce behavioral deficits following 6-hydroxydopamine lesions, but not 6-hydroxydopamine-induced dopamine depletion. These data support a potential neuroprotective effect of low levels of PAR1 activation, which may engage neuroprotective intracellular pathways or down-regulate surface expression of PAR1. However, the pathophysiology of Parkinson's disease and MPTP-induced damage is complex, with hypothesized roles for both neurons and glia (Beal, 2003; Wu et al., 2003) in addition to a range of molecular mechanisms including oxidative stress, inflammation, and mitochondrial dysfunction. Our findings that PAR1 removal or block can protect dopaminergic nerve terminal damage support the idea that PAR1 can have multiple effects, some of which exacerbate nerve terminal damage in the MPTP model of Parkinson's disease. We expect the harmful PAR1-linked mechanisms that contribute to terminal damage following the modest MPTP dosing paradigm

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

used here will also be engaged in models of parkinsonism employing higher MPTP doses that lead to substantial neuronal loss.

MPTP-induced degeneration of the dopaminergic system has long been known not to cause direct detectable breakdown of the blood-brain barrier (Adams et al., 1989; O'Callaghan et al., 1990; Kurkowska-Jastrzebska et al., 1999; Nicole et al., 2005). Our data are consistent with this view, and support the idea that breakdown of the blood-brain barrier is unlikely to influence the effects of PAR1 in the acute MPTP model of Parkinson's disease. However, environmental factors such as head trauma and infection may increase the risk of developing Parkinson's disease (Taylor et al., 1999; Mayeux, 2003). Interestingly, both head trauma and infection should temporarily increase permeability of the blood-brain barrier long before onset of Parkinson's disease, allowing blood-derived serine proteases access to brain tissue. Our data further raise the possibility that activation of PAR1 in brain parenchyma could stimulate microglial activation, perhaps increasing inflammatory processes that may favor initial nerve terminal damage and thereby elevating the risk of Parkinson's disease.

Ishida et al. (2006) have suggested that Parkinson's disease is associated with an upregulation of PAR1 and an increase in potential expression of PAR1 activators. In general agreement with these data, we have found administration of MPTP alters the brain serine protease system in favor of PAR1 activation, although we did not detect increased PAR1 expression. Rather we find upregulation of several PAR1 activators, and propose these changes exacerbate harmful actions of MPTP via their activation of PAR1. MMP1, which has been shown to have a role in substantia nigral disorders, can activate PAR1 directly (Gardner and Ghorpade, 2003; Lorenzl et al., 2004; Shi et al., 2004; Boire et al., 2005). Factor Xa also can activate PAR1, and additionally can convert prothrombin to thrombin, which is a potent PAR1 activator (Jones and Geczy, 1990; Yamada and Nagai, 1996; Shikamoto and Morita, 1999). Factor X is activated by Factor VIIa and Factor IXa, which also may be present in the CNS, although this has not been studied extensively. However, macrophages produce and release a Factor VII-like protein that activates Factor X (Shands, 1983; Tsao et al., 1984; Shands, 1985). Several reports suggest that MMP1 and Factor X can be made by microglia and astrocytes (Nakagawa et al., 1994; Yamada and Nagai, 1996; Shikamoto and Morita,

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

1999; Ghorpade et al., 2001; Lorenzl et al., 2002; Gardner and Ghorpade, 2003; Kunapuli et al., 2004; Lorenzl et al., 2004; Hamill et al., 2005; McCready et al., 2005). In addition, there is strong evidence that prothrombin, the precursor to thrombin, is expressed throughout the CNS (Soifer et al., 1994; Weinstein et al., 1995). Ishida et al report an increase in prothrombin expressing astrocytes in substantia nigra from Parkinson's patients. With increased levels of Factor X, we would predict increased activation of thrombin and consequent PAR1 signaling. Similarly, we found a decrease in plasminogen activator inhibitor-1 expression. This could enhance conversion of plasminogen to plasmin in the central nervous system, which has been shown to play a role in learning and memory, synaptic plasticity, and neuronal damage. Furthermore, plasmin is also known to cleave and activate PAR1 (Sharon et al., 2002; Pang et al., 2004; Nagai et al., 2005). Together, these changes indicate that the MPTP-induced toxicity causes a shift in the protease system of the brain towards PAR1 activation.

Microglia and Parkinson's disease

The data presented here are consistent with the idea that microglial activation is detrimental to neuronal survival in the MPTP model of Parkinson's disease. Although it is not clear if the reduced microglial response in PAR1-/- mice reflects a reduction in neuronal damage and consequent inflammatory response, we note that astrogliosis is unaffected by the absence of PAR1 in this model. The role of microglia in the pathogenesis of Parkinson's disease has been an area of active investigation. Several groups have reported that activation of microglia with substances such as lipopolysaccharide or thrombin, a potent PAR1 agonist, can lead to dopaminergic neuronal death that is due in part to release of cytokines (Adams et al., 1989; Gayle et al., 2002; Carreno-Muller et al., 2003; Choi et al., 2003ab; Gao et al., 2003; Qin et al., 2004; Lee da et al., 2005). Likewise, others have found that pharmacologic inhibition of microglia, for example with minocycline, protected against neurotoxins like MPTP and thrombin, although the non-microglial-specific effects of such drugs may have other actions (Du et al., 2001; Wu et al., 2002; Yang et al., 2003; Diguet et al., 2004; Choi et al., 2005). The ability of PAR1 stimulation to activate microglia (Suo et al., 2002) coupled with the findings presented in this study further support a role for inflammation as a mediator

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

of dopaminergic terminal damage in the parkinsonian brain. Clearly more work is needed to both elucidate the nature by which microglia promote projection terminal degeneration, as well as clarify the role of PAR1 and other protease receptors on microglia. Although our experiments with acute intracerebroventricular administration of the PAR1 antagonist BMS-200261 support our working hypothesis, the lack of brain penetration of the modified peptide limits experimental design. If brain penetrable PAR1 antagonists were available, a number of important questions could be addressed about the role of PAR1 in chronic neuroinflammation.

Despite advances in our understanding of Parkinson's disease, therapy is still limited to the treatment of symptoms; no medication to date slows the progression of the disease in patients. Recent studies using transgenic mice have begun to identify key molecular components in the progression of Parkinson's disease. Mice lacking pro-inflammatory signaling components are partially protected from MPTP-induced damage (Rousselet et al., 2002; Wu et al., 2003; Ferger et al., 2004; Hebert et al., 2005). The results presented here provide further evidence that serine proteases and their receptors may have a role in dopamine neuron toxicity as it relates to Parkinson's disease. These data offer a reasonable link between events that disrupt the blood-brain barrier and the future risk of development of Parkinson's disease (Mayeux, 2003). Moreover, these data place PAR1 among only a handful of therapeutically tractable drug targets (Chen et al., 2001; Xu et al., 2005) that can slow or halt MPTP-induced damage (Chen et al., 2001; Rousselet et al., 2002; Hebert et al., 2005). Indeed, blockade of PAR1 may represent a novel therapeutic approach to slow disease progression in a Parkinson's patient or decrease disease incidence in at-risk patient populations.

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

Acknowledgment

We thank Dr. Daniel Brat for helpful discussions, the Emory Alzheimer's Disease Research Center (AG025688), and Drs. Marla Gearing, Allan Levey, Howard Rees, Veronica Walker for assistance with human immunohistochemistry. We also thank Drs. Terrilyn Richardson and Min Wang for assistance with RT-PCR, as well as Polina Lyuboslavsky, Phoung Le, Antoine Almonte, and Georgia Taylor for excellent technical assistance.

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

References

Adams JD, Jr., Kalivas PW and Miller CA (1989) The acute histopathology of MPTP in the mouse CNS. *Brain Res Bull* **23**(1-2):1-17.

Altrogge LM and Monard D (2000) An assay for high-sensitivity detection of thrombin activity and determination of proteases activating or inactivating protease-activated receptors. *Anal Biochem* **277**(1):33-45.

Aubin N, Curet O, Deffois A and Carter C (1998) Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. *J Neurochem* **71**(4):1635-1642.

Beal MF (2003) Mitochondria, oxidative damage, and inflammation in Parkinson's disease. *Ann N Y Acad Sci* **991**:120-131.

Bernatowicz MS, Klimas CE, Hartl KS, Peluso M, Allegretto NJ and Seiler SM (1996) Development of potent thrombin receptor antagonist peptides. *J Med Chem* **39**(25):4879-4887.

Blackhart BD, Cuenco G, Toda T, Scarborough RM, Wolf DL and Ramakrishnan V (1994) The anion-binding exosite is critical for the high affinity binding of thrombin to the human thrombin receptor. *Growth Factors* **11**(1):17-28.

Blanc-Brude OP, Chambers RC, Leoni P, Dik WA and Laurent GJ (2001) Factor Xa is a fibroblast mitogen via binding to effector-cell protease receptor-1 and autocrine release of PDGF. *Am J Physiol Cell Physiol* **281**(2):C681-689.

Boire A, Covic L, Agarwal A, Jacques S, Sherifi S and Kuliopulos A (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. *Cell* **120**(3):303-313.

Cannon JR, Keep RF, Hua Y, Richardson RJ, Schallert T, Xi G (2005) Thrombin preconditioning provides protection in a 6-hydroxydopamine Parkinson's disease model. *Neurosci. Lett* **373**: 189-194.

Cannon JR, Keep RF, Schallert T, Hua Y, Richardson RJ, Xi G (2006) Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease. *Brain Research* **1116**: 177-186.

Carreno-Muller E, Herrera AJ, de Pablos RM, Tomas-Camardiel M, Venero JL, Cano J and Machado A (2003) Thrombin induces in vivo degeneration of nigral dopaminergic neurones along with the activation of microglia. *J Neurochem* **84**(5):1201-1214.

Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE and Ascherio A (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. *Arch Neurol* **60**(8):1059-1064.

Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N, Jr. and Schwarzschild MA (2001) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. *J Neurosci* **21**(10):RC143.

Choi SH, Joe EH, Kim SU and Jin BK (2003a) Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neurons in vivo. *J Neurosci* **23**(13):5877-5886.

Choi SH, Lee DY, Ryu JK, Kim J, Joe EH, Jin BK (2003b) Thrombin induces nigral dopaminergic neurodegeneration in vivo by altering expresion of death-related proteins. *Neurobiology of Disease* **14**: 181-193.

Choi SH, Lee DY, Chung ES, Hong YB, Kim SU, Jin BK (2005) Inhibition of thrombin-induced microglial activation and NADPH oxidase by minocycline protects dopaminergic neurons in the substantia nigra *in vivo*. *J Neurochem* **95**: 1755-65.

Coffey LL and Reith ME (1994) [3H]WIN 35,428 binding to the dopamine uptake carrier. I. Effect of tonicity and buffer composition. *J Neurosci Methods* **51**(1):23-30.

Connolly AJ, Ishihara H, Kahn ML, Farese RV, Jr. and Coughlin SR (1996) Role of the thrombin receptor in development and evidence for a second receptor. *Nature* **381**(6582):516-519.

Czlonkowska A, Kohutnicka M, Kurkowska-Jastrzebska I and Czlonkowski A (1996) Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. *Neurodegeneration* **5**(2):137-143.

Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E and Tison F (2004) Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. *Eur J Neurosci* **19**(12):3266-3276.

Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP and Paul SM (2001) Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. *Proc Natl Acad Sci U S A* **98**(25):14669-14674.

Elwan MA, Richardson JR, Guillot TS, Caudle WM and Miller GW (2006) Pyrethroid pesticide-induced alterations in dopamine transporter function. *Toxicol Appl Pharmacol*. **211**(3):188-97.

Ferger B, Leng A, Mura A, Hengerer B and Feldon J (2004) Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. *J Neurochem* **89**(4):822-833.

Francis JW, Von Visger J, Markelonis GJ and Oh TH (1995) Neuroglial responses to the dopaminergic neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse striatum. *Neurotoxicol Teratol* **17**(1):7-12.

Fujimoto S, Katsuki H, Kume T, Akaike A (2006) Thrombin-induced delayed injury involves multiple and distinct signaling pathways in the cerebral cortex and the striatum in organotypic slice cultures. *Neurobiol of Disease* 22: 130-142.

Gao HM, Liu B, Zhang W and Hong JS (2003) Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. *Faseb J* **17**(13):1957-1959.

Gardner J and Ghorpade A (2003) Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. *J Neurosci Res* **74**(6):801-806.

Gayle DA, Ling Z, Tong C, Landers T, Lipton JW and Carvey PM (2002) Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. *Brain Res Dev Brain Res* **133**(1):27-35.

Ghorpade A, Persidskaia R, Suryadevara R, Che M, Liu XJ, Persidsky Y and Gendelman HE (2001) Mononuclear phagocyte differentiation, activation, and viral infection regulate matrix metalloproteinase expression: implications for human immunodeficiency virus type 1-associated dementia. *J Virol* **75**(14):6572-6583.

Gingrich MB and Traynelis SF (2000) Serine proteases and brain damage - is there a link? *Trends Neurosci* **23**(9):399-407.

Giovanni A, Sieber BA, Heikkila RE and Sonsalla PK (1991) Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. *J Pharmacol Exp Ther* **257**(2):691-697.

Hamill CE, Goldshmidt A, Nicole O, McKeon RJ, Brat DJ and Traynelis SF (2005) Special lecture: glial reactivity after damage: implications for scar formation and neuronal recovery. *Clin Neurosurg* **52**:29-44.

Hebert G, Mingam R, Arsaut J, Dantzer R and Demotes-Mainard J (2005) A role of IL-1 in MPTP-induced changes in striatal dopaminergic and serotoninergic transporter binding: clues from interleukin-1 type I receptor-deficient mice. *Brain Res Mol Brain Res* **136**(1-2):267-270.

Hof PR, Young WG, Bloom FE, Belichenko PV and Celio MR (2000) *Comparative cytoarchitectonic atlas of C57Bl/6 and 129/SV Mouse Brain*. Elsevier, New York City.

Hollenberg MD, Saifeddine M, al-Ani B, Kawabata A. Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides. Can J Physiol Pharmacol. 1997 Jul;75(7):832-41.

Hollenberg MD (2002) PARs in the stars: proteinase-activated receptors and astrocyte function. Focus on "Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways". *Am J Physiol Cell Physiol* **283**(5):C1347-1350.

Ishida Y, Nagai A, Kobayashi S, Kim SU (2006) Upregulation of protease-activated receptor-1 in astrocytes in Parkinson's Disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. *J Neuropathol Exp Neurol* 65 66-77.

Jiang X, Bailly MA, Panetti TS, Cappello M, Konigsberg WH and Bromberg ME (2004) Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells. *J Thromb Haemost* **2**(1):93-101.

Jones A and Geczy CL (1990) Thrombin and factor Xa enhance the production of interleukin-1. *Immunology* **71**(2):236-241.

Junge CE, Lee CJ, Hubbard KB, Zhang Z, Olson JJ, Hepler JR, Brat DJ and Traynelis SF (2004) Protease-activated receptor-1 in human brain: localization and functional expression in astrocytes. *Exp Neurol* **188**(1):94-103.

Junge CE, Sugawara T, Mannaioni G, Alagarsamy S, Conn PJ, Brat DJ, Chan PH and Traynelis SF (2003) The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. *Proc Natl Acad Sci U S A* **100**(22):13019-13024.

Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B and Hong JS (2000) Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. *J Neurosci* **20**(16):6309-6316.

Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A and Czlonkowska A (1998) Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). *Immunopharmacology* **39**(3):167-180.

Kuliopulos A, Covic L, Seeley SK, Sheridan PJ, Helin J and Costello CE (1999) Plasmin desensitization of the PAR1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. *Biochemistry* **38**(14):4572-4585.

Kunapuli P, Kasyapa CS, Hawthorn L and Cowell JK (2004) LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. *J Biol Chem* **279**(22):23151-23157.

Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A and Czlonkowska A (1999) The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. *Exp Neurol* **156**(1):50-61.

Langston JW, Ballard P, Tetrud JW and Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* **219**(4587):979-980.

Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA and Karluk D (1999) Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. *Ann Neurol* **46**(4):598-605.

Lawson LJ, Perry VH, Dri P and Gordon S (1990) Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. *Neuroscience* **39**(1):151-170.

Lee da Y, Oh YJ and Jin BK (2005) Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways. *Glia* **51**(2):98-110.

Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM and Przedborski S (1999) Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. *Nat Med* **5**(12):1403-1409.

Liu LW, Vu TK, Esmon CT and Coughlin SR (1991) The region of the thrombin receptor resembling hirudin binds to thrombin and alters enzyme specificity. *J Biol Chem* **266**(26):16977-16980.

Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* **25**(4):402-408.

Lorenzl S, Albers DS, Narr S, Chirichigno J and Beal MF (2002) Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. *Exp Neurol* **178**(1):13-20.

Lorenzl S, Albers DS, Chirichigno JW, Augood SJ and Beal MF (2004) Elevated levels of matrix metalloproteinases-9 and -1 and of tissue inhibitors of MMPs, TIMP-1 and TIMP-2 in postmortem brain tissue of progressive supranuclear palsy. *J Neurol Sci* **218**(1-2):39-45.

Macfarlane SR, Seatter MJ, Kanke T, Hunter GD and Plevin R (2001) Proteinase-activated receptors. *Pharmacol Rev* **53**(2):245-282.

Mayeux R (2003) Epidemiology of neurodegeneration. *Annu Rev Neurosci* **26**:81-104.

McCready J, Broaddus WC, Sykes V and Fillmore HL (2005) Association of a single nucleotide polymorphism in the matrix metalloproteinase-1 promoter with glioblastoma. *Int J Cancer* **117**(5):781-785.

McGeer PL, Itagaki S, Boyes BE and McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. *Neurology* **38**(8):1285-1291.

McGeer PL, Schwab C, Parent A and Doudet D (2003) Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. *Ann Neurol* **54**(5):599-604.

Nagai T, Kamei H, Ito M, Hashimoto K, Takuma K, Nabeshima T and Yamada K (2005) Modification by the tissue plasminogen activator-plasmin system of morphine-induced dopamine release and hyperlocomotion, but not anti-nociceptive effect in mice. *J Neurochem* **93**(5):1272-1279.

Nakagawa T, Kubota T, Kabuto M, Sato K, Kawano H, Hayakawa T and Okada Y (1994) Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. *J Neurosurg* **81**(1):69-77.

Niclou SP, Suidan HS, Pavlik A, Vejsada R and Monard D (1998) Changes in the expression of protease-activated receptor 1 and protease nexin-1 mRNA during rat nervous system development and after nerve lesion. *Eur J Neurosci* **10**(5):1590-1607.

Nicole O, Goldshmidt A, Hamill CE, Sorensen SD, Sastre A, Lyuboslavsky P, Hepler JR, McKeon RJ and Traynelis SF (2005) Activation of protease-activated receptor-1 triggers astrogliosis after brain injury. *J Neurosci* **25**(17):4319-4329.

O'Callaghan JP, Miller DB and Reinhard JF, Jr. (1990) Characterization of the origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Brain Res* **521**(1-2):73-80.

Olanow CW and Tatton WG (1999) Etiology and pathogenesis of Parkinson's disease. *Annu Rev Neurosci* **22**:123-144.

Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T and Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. *Ann Neurol* **57**(2):168-175.

Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, Teng KK, Yung WH, Hempstead BL and Lu B (2004) Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. *Science* **306**(5695):487-491.

Payne J, Maher F, Simpson I, Mattice L and Davies P (1997) Glucose transporter Glut 5 expression in microglial cells. *Glia* **21**(3):327-331.

Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, Liu B and Hong JS (2004) NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. *J Biol Chem* **279**(2):1415-1421.

Richardson JR and Miller GW (2004) Acute exposure to aroclor 1016 or 1260 differentially affects dopamine transporter and vesicular monoamine transporter 2 levels. *Toxicol Lett* **148**(1-2):29-40.

Riewald M, Petrovan RJ, Donner A, Mueller BM and Ruf W (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. *Science* **296**(5574):1880-1882.

Rommelfanger KS, Weinshenker D and Miller GW (2004) Reduced MPTP toxicity in noradrenaline transporter knockout mice. *J Neurochem* **91**(5):1116-1124.

Rousselet E, Callebert J, Parain K, Joubert C, Hunot S, Hartmann A, Jacque C, Perez-Diaz F, Cohen-Salmon C, Launay JM and Hirsch EC (2002) Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. *Exp Neurol* **177**(1):183-192.

Ruf W (2003) PAR1 signaling: more good than harm? *Nat Med* **9**(3):258-260.

Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL and Isacson O (2004) Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. *J Neuroinflammation* **1**(1):6.

Saporito MS, Brown EM, Miller MS and Carswell S (1999) CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. *J Pharmacol Exp Ther* **288**(2):421-427.

Schmidt-Kastner R, Meller D, Bellander BM, Stromberg I, Olson L and Ingvar M (1993) A one-step immunohistochemical method for detection of blood-brain barrier disturbances for immunoglobulins in lesioned rat brain with special reference to false-positive labelling in immunohistochemistry. *J Neurosci Methods* **46**(2):121-132.

Schmidt N and Ferger B (2001) Neurochemical findings in the MPTP model of Parkinson's disease. *J Neural Transm* **108**(11):1263-1282.

Shands JW, Jr. (1983) The endotoxin-induced procoagulant of mouse exudate macrophages: a factor-X activator. *Blood* **62**(2):333-340.

Shands JW, Jr. (1985) Macrophage factor X activator formation: metabolic requirements for synthesis of components. *Blood* **65**(1):169-175.

Sharon R, Abramovitz R and Miskin R (2002) Plasminogen mRNA induction in the mouse brain after kainate excitation: codistribution with plasminogen activator inhibitor-2 (PAI-2) mRNA. *Brain Res Mol Brain Res* **104**(2):170-175.

Shi X, Gangadharan B, Brass LF, Ruf W and Mueller BM (2004) Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. *Mol Cancer Res* **2**(7):395-402.

Shikamoto Y and Morita T (1999) Expression of factor X in both the rat brain and cells of the central nervous system. *FEBS Lett* **463**(3):387-389.

Soifer SJ, Peters KG, O'Keefe J and Coughlin SR (1994) Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. *Am J Pathol* **144**(1):60-69.

Sorensen SD, Nicole O, Peavy RD, Montoya LM, Lee CJ, Murphy TJ, Traynelis SF and Hepler JR (2003) Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. *Mol Pharmacol* **64**(5):1199-1209.

Suo Z, Wu M, Ameenuddin S, Anderson HE, Zoloty JE, Citron BA, Andrade-Gordon P and Festoff BW (2002) Participation of protease-activated receptor-1 in thrombin-induced microglial activation. *J Neurochem* **80**(4):655-666.

Suo Z, Citron BA and Festoff BW (2004) Thrombin: a potential proinflammatory mediator in neurotrauma and neurodegenerative disorders. *Curr Drug Targets Inflamm Allergy* **3**(1):105-114.

Taylor CA, Saint-Hilaire MH, Cupples LA, Thomas CA, Burchard AE, Feldman RG and Myers RH (1999) Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. *Am J Med Genet* **88**(6):742-749.

Tillerson JL, Caudle WM, Reveron ME and Miller GW (2002) Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Exp Neurol* **178**(1):80-90.

Tsao BP, Fair DS, Curtiss LK and Edgington TS (1984) Monocytes can be induced by lipopolysaccharide-triggered T lymphocytes to express functional factor VII/VIIa protease activity. *J Exp Med* **159**(4):1042-1057.

Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, Tieu K and Przedborski S (2001) The role of glial cells in Parkinson's disease. *Curr Opin Neurol* **14**(4):483-489.

Vu TK, Wheaton VI, Hung DT, Charo I and Coughlin SR (1991) Domains specifying thrombin-receptor interaction. *Nature* **353**(6345):674-677.

Wang H and Reiser G (2003) Thrombin signaling in the brain: the role of protease-activated receptors. *Biol Chem* **384**(2):193-202.

Wang H, Ubl JJ and Reiser G (2002a) Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. *Glia* **37**(1):53-63.

Wang H, Ubl JJ, Stricker R and Reiser G (2002b) Thrombin (PAR-1)-induced proliferation in astrocytes via MAPK involves multiple signaling pathways. *Am J Physiol Cell Physiol* **283**(5):C1351-1364.

Weinstein JR, Gold SJ, Cunningham DD and Gall CM (1995) Cellular localization of thrombin receptor mRNA in rat brain: expression by mesencephalic dopaminergic neurons and codistribution with prothrombin mRNA. *J Neurosci* **15**(4):2906-2919.

Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H and Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. *J Neurosci* **22**(5):1763-1771.

Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H and Przedborski S (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. *Proc Natl Acad Sci U S A* **100**(10):6145-6150.

Xu K, Bastia E and Schwarzschild M (2005) Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. *Pharmacol Ther* **105**(3):267-310.

Yamada T and Nagai Y (1996) Immunohistochemical studies of human tissues with antibody to factor Xa. *Histochem J* **28**(1):73-77.

Yang L, Sugama S, Chirichigno JW, Gregorio J, Lorenzl S, Shin DH, Browne SE, Shimizu Y, Joh TH, Beal MF and Albers DS (2003) Minocycline enhances MPTP toxicity to dopaminergic neurons. *J Neurosci Res* **74**(2):278-285.

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

Footnotes

Finacial support

This work was supported by NIH R01 NS36654 (SFT), NIH R01 NS39419 (SFT), NIH R21 ES012315 (GWM), NIH U54 ES012068 (GWM) as part of the Collaborative Centers for Parkinson's Disease Environmental Research (CCPDER), a pilot grant from the CCPDER (SFT), NARSAD (SFT), the Michael J. Fox Foundation (SFT), the Georgia Tech Foundation (KDP), NIH fellowships F30 NS530062 (CEH) and F32 ES013457 (JRR), NIH K08 NS048858 (JGG), NIH T32 ES012879 (WMC), and a Cotzias Fellowship from the American Parkinson Disease Association (JGG). SFT is a co-inventor on patent-pending technology involving PAR1.

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

Legends for Figures

Figure 1. *PAR1-/- mice are structurally protected against MPTP-induced damage.* (a) Immunohistochemistry for dopamine transporter (DAT) and tyrosine hydroxylase (TH) show that MPTP treatment reduced staining in wild-type mice, whereas PAR1-/- mice resemble saline controls following 2 days survival. Staining was visualized with diaminobenzadine (Ctx=cortex, Str=striatum, AC=anterior commisure). Scale bar represents 500 μm. (b-d) The quantification of DAT and TH immunoblots is shown. Wild-type (WT) mice expressed significantly less DAT and TH (**p<0.01; 2-factor ANOVA; n=4-8) following MPTP-treatment than their PAR1-/- counterparts at 2 (b), 7 (c), and 30 (d) days survival. *Inset*—Representative immunoblot showing DAT and TH protein levels compared to tubulin levels (Tub).

Figure 2. *PAR1-/- mice are functionally protected against MPTP-induced damage.* (a) PAR1-/- mice have significantly more striatal dopamine (DA) following MPTP than wild-type mice (2-day survival 9.5±1.0 ng/mg tissue in wild-type mice versus 13.4±0.8 ng/mg tissue PAR1-/- mice; **p<0.01; 2-factor ANOVA; n=7-8). (b-c) Higher levels of dopamine are observed in PAR1-/- mice at 7 days survival (6.7±0.4 ng/mg tissue in wild-type mice versus 10.4±0.7 ng/mg tissue in PAR1-/- mice; ***p<0.001; 2-factor ANOVA; n=4-8) and after 30 days survival (9.0±0.4 ng/mg tissue in wild-type mice versus 13.6±0.4 ng/mg tissue in PAR1-/- mice; ***p<0.001; 2-factor ANOVA).

Figure 3. W*ild-type mice receiving a PAR1 antagonist are structurally and functionally protected against MPTP-induced damage.* (a) Wild-type mice implanted with a minipump loaded with the PAR1 antagonist BMS-200261 show increased levels of DAT (**p<0.01; 1-factor ANOVA; n=6-8) and TH (*p<0.05; 1-factor ANOVA; n=6-8) following MPTP treatment compared to wild-type mice not treated with PAR1 antagonist. (b) PAR1 antagonist-treated mice have significantly more striatal dopamine following MPTP administration than control mice (11.2±0.7 ng/mg in control mice and 15.5±0.7 ng/mg in mice receiving BMS-200261; **p<0.01; 1-factor ANOVA; n=2-6).

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

Figure 4. *PAR1-/- mice have dampened microglial responses but normal astrocyte responses to MPTP*. (a) Staining for MAC-1(CD11b) shows that wild-type mice have more reactive striatal microglia following MPTP that PAR1-/- mice (n=3); scale bar 200 μm. (b) Immunoblot shows higher levels of GLUT5 protein, a microglial marker, in wild-type (WT) mice than in PAR1-/- mice following MPTP treatment (**$p<0.01$; 2-factor ANOVA; n=6-8). (c) GFAP staining shows no differences in astrocytic response in WT and PAR1-/- mice seven days after MPTP treatment; scale bar 500 μm. (d) Immunoblot analysis of GFAP shows no significant difference between genotypes ($p>0.05$; 2-factor ANOVA; n=6-8).

Figure 5. *Baseline microglial populations and post-MPTP blood-brain-barrier breakdown*. (a) There were no differences between wild-type (WT) and PAR1-/- IB4-lectin stain, which labels all microglia regardless of activation state; scale bar 100 μm. (b) Following MPTP treatment, there was no detectable opening of the barrier in striatum (Str), as determined by IgG staining; scale bar 500 μm. *Inset*—Median eminence (ME) serves as a positive control, since blood-brain-barrier is absent in this region.

Figure 6. *PAR1 protein co-localizes with tyrosine hydroxylase in normal human substantia nigra pars compacta and is functionally expressed in mouse dopaminergic neurons.* (a) A representative photomicrograph of PAR1 (upper panel) and tyrosine-hydroxylase (TH, middle panel) staining and their overlay (lower panel) is shown. The main panels show 20x magnifications (scale bar 100μm); insets show 40x magnifications (scale bar 10 μm). Most neurons that stain for TH also show PAR1 expression. There are some TH-positive cells that are negative for PAR1 (cell on right in upper insets; from a different field of view) and some PAR1 positive cells that do not stain for TH (cell on right in lower inset). Data are representative of 4 different experiments. (b) Representative images showing that TFLLR (right panels) but not vehicle (left panels) causes increased phospho-ERK expression in tyrosine-hydroxylase expressing neurons. Upper panels show phospho-ERK staining, middle panels show TH staining, and lower panels show overlay. Circles show cells co-expressing PAR1 and TH.

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

Table 1: MPTP increases the mRNA levels of PAR1 activators

	Wild-type	PAR1-/-
Protease Receptors		
PAR1	114±16	nd
PAR2	107±39	70±18
PAR3	95±8	89±12
PAR4	84±20	124±15
Proteases		
Prothrombin	124±36	107±18.
Plasminogen	138±58	93±21
Tissue plasminogen activator	119±20	82±8
Matrix metalloprotease 1	201±15 *	248±18 *
Factor X	283±65 **	345±55 **
Factor VII	94±19	74±5
Neurotrypsin	99±13	84±24
Protein C	76±12	104±22
Protease inhibitors		
Neuroserpin	118±25	105±16
Protease nexin 1	128±23	124±20
Plasminogen activator inhibitor 1	55±13 *	52±10 *
Tissue inhibitor of matrix metalloprotease-1	90±47	93±21

Real time reverse transcriptase PCR measurements of mRNA relative to 18S mRNA are expressed as a percent of saline-injected controls. PAR1 signal was only found in wild-type mice. For all, n=4. *treatment $p<0.05$; **treatment $p<0.01$, 2-factor ANOVA; nd is not determined. There was no significant difference between genotypes.

Molecular Pharmacology Fast Forward. Published on June 27, 2007 as DOI: 10.1124/mol.107.038158
This article has not been copyedited and formatted. The final version may differ from this version.

Table 2: Wild-type and PAR1-/- mice show baseline similarities in the dopaminergic system

	Wild-type	PAR1-/-
^{3}H-WIN Binding (fmol/mg protein)	984±39	1014±36
^{3}H-DA Uptake (pmol/min-mg protein)	309±9	306±17
^{3}H-MPP+ Uptake (pmol/min-mg protein)	198±13	195±18
MPP+ Levels (ng/mg striatal tissue)	3.5±0.3	3.2±0.2

All studies were performed in triplicate with at least three animals per group. No significant differences were found between the wild-type and PAR1-/- values (t-test)


a
DAT
Ctx
Str
AC
WT Saline
-/- Saline
WT MPTP
-/- MPTP
TH
WT Saline
-/- Saline
WT MPTP
-/- MPTP
b
TH
DAT
DAT
TH
Tub
**
**
Percent control
(2 days survival)
100
50
0
WT
Saline
PAR1-/-
Saline
WT
MPTP
PAR1-/-
MPTP
c
TH
DAT
**
**
Percent control
(7 days survival)
100
50
0
WT
Saline
PAR1-/-
Saline
WT
MPTP
PAR1-/-
MPTP
d
TH
DAT
**
**
Percent control
(30 days survival)
100
50
0
WT
Saline
PAR1-/-
Saline
WT
MPTP
PAR1-/-
MPTP

Figure 1


a
Dopamine (ng/mg)
(2 days survival)
20
10
0
**
WT
Saline
PAR1-/-
Saline
WT
MPTP
PAR1-/-
MPTP
b
Dopamine (ng/mg)
(7 days survival)
20
10
0
***
WT
Saline
PAR1-/-
Saline
WT
MPTP
PAR1-/-
MPTP
c
Dopamine (ng/mg)
(30 days survival)
20
10
0
***
WT
Saline
PAR1-/-
Saline
WT
MPTP
PAR1-/-
MPTP

Figure 2


a
TH
DAT
*
**
Percent control
(+/- antagonist)
100
50
0
Control
Saline
Control
MPTP
Antagonist
MPTP
b
**
Dopamine (ng/mg)
(+/- antagonist)
20
10
0
Control
Saline
Control
MPTP
Antagonist
MPTP

Figure 3


a
MAC-1(CD11b) staining
Wild type saline
PAR1-/- saline
Wild type MPTP
PAR1-/- MPTP
c
GFAP staining
Wild type saline
PAR1-/- saline
Wild type MPTP
PAR1-/- MPTP
b
Percent GLUT5 protein
200
100
0
**
WT Saline
PAR1-/- Saline
WT MPTP
PAR1-/- MPTP
d
Percent GFAP protein
200
100
0
ns
WT Saline
PAR1-/- Saline
WT MPTP
PAR1-/- MPTP

Figure 4


a
IB4-lectin stain for microglia
WT
Saline
PAR1-/-
Saline
b
Blood-brain barrier breakdown
v
Str
ME
WT
MPTP
v
Str
ME
PAR1-/-
MPTP

Figure 5


a
PAR1 expression
in human SNc
b
PAR1-stimulated ERK
phosphorylation in mouse
dopaminergic neurons
Vehicle
TFLLR
PAR1
ERK
ERK
TH
TH
TH
Overlay
Overlay
Overlay

Figure 6